{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:29:46Z","timestamp":1779917386962,"version":"3.53.1"},"reference-count":38,"publisher":"Becaris Publishing Limited","issue":"14","funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>In this study, we assessed the productivity gains associated with the use of obinutuzumab in combination with chemoimmunotherapy (G-chemo) in first-line treatment among follicular lymphoma patients. Health benefits, measured as an increase in progression-free survival, were translated into productivity gains in both paid and unpaid work using gross value added\u00a0as productivity measure. From 2017 to 2030, 11,870 overall progression-free years can be gained by utilizing obinutuzumab. These progression-free years correspond to undiscounted productivity gains of about \u20ac187.9\u00a0million in paid work and about \u20ac535.9\u00a0million in unpaid work. Our study shows that the benefits of the use of obinutuzumab in the first-line treatment of follicular lymphoma extend beyond clinical advantages.<\/jats:p>","DOI":"10.2217\/cer-2020-0131","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T10:18:09Z","timestamp":1601893089000},"page":"1017-1026","source":"Crossref","is-referenced-by-count":3,"title":["The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany"],"prefix":"10.57264","volume":"9","author":[{"given":"Sarah","family":"Hofmann","sequence":"first","affiliation":[{"name":"WifOR Institute, Darmstadt, 64283, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Himmler","sequence":"additional","affiliation":[{"name":"WifOR Institute, Darmstadt, 64283, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Ostwald","sequence":"additional","affiliation":[{"name":"WifOR Institute, Darmstadt, 64283, Germany"},{"name":"Steinbeis, School of International Business &amp;\u00a0Entrepreneurship (SIBE), Herrenberg, 71083, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fcnzinger","sequence":"additional","affiliation":[{"name":"Roche Pharma AG, Grenzach-Wyhlen, 79639, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"Launonen","sequence":"additional","affiliation":[{"name":"F. Hoffman-La Roche Ltd, Basel, 4070, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Olof","family":"Thuresson","sequence":"additional","affiliation":[{"name":"F. Hoffman-La Roche Ltd, Basel, 4070, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_3_3_2","article-title":"Follikul\u00e4res non-hodgkin-lymphom (ICD-10 Code C82)","author":"Robert Koch Institute","year":"2018","unstructured":"Robert Koch Institute. Follikul\u00e4res non-hodgkin-lymphom (ICD-10 Code C82). Zentrum F\u00fcr Krebsregisterdaten (2018). http:\/\/www.krebsdaten.de\/abfrage","journal-title":"Zentrum F\u00fcr Krebsregisterdaten"},{"issue":"1","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/pon.1194","article-title":"Work disability associated with cancer survivorship and other chronic conditions","volume":"17","author":"Short PF","year":"2008","unstructured":"Short PF, Vasey JJ, BeLue R. Work disability associated with cancer survivorship and other chronic conditions. Psychooncology 17(1), 91\u201397 (2008).","journal-title":"Psychooncology"},{"issue":"3","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00043764-200103000-00009","article-title":"The effects of chronic medical conditions on work loss and work cutback","volume":"43","author":"Kessler RC","year":"2001","unstructured":"Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. The effects of chronic medical conditions on work loss and work cutback. J. Occup. Environ. Med. 43(3), 218 (2001).","journal-title":"J. Occup. Environ. Med."},{"issue":"6","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/occmed\/kqp088","article-title":"Employment and the common cancers: correlates of work ability during or following cancer treatment","volume":"59","author":"Munir F","year":"2009","unstructured":"Munir F, Yarker J, McDermott H. Employment and the common cancers: correlates of work ability during or following cancer treatment. Occup. Med. 59(6), 381\u2013389 (2009).","journal-title":"Occup. Med."},{"issue":"4","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus R","year":"2005","unstructured":"Marcus R, Imrie K, Belch A CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4), 1417\u20131423 (2005).","journal-title":"Blood"},{"issue":"28","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus R","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 26(28), 4579\u20134586 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann W","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725\u20133732 (2005).","journal-title":"Blood"},{"issue":"7","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1080\/10428194.2018.1551532","article-title":"Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States","volume":"60","author":"Guzauskas GF","year":"2019","unstructured":"Guzauskas GF, Masaquel A, Thuresson P-O, Dawson K, Veenstra DL. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. Leuk. Lymphoma 60(7), 1668\u20131676 (2019).","journal-title":"Leuk. Lymphoma"},{"issue":"14","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus R","year":"2017","unstructured":"Marcus R, Davies A, Ando K Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med. 377(14), 1331\u20131344 (2017).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_12_2","volume-title":"Allgemeine Sterbetafel 2010\/12.","author":"Destatis","year":"2015","unstructured":"Destatis. Allgemeine Sterbetafel 2010\/12. Statistisches Bundesamt, Wiesbaden, Germany (2015)."},{"key":"e_1_3_3_13_2","unstructured":"EMA. European Public Assessment Report (EPAR) for Gazyvaro Annex I \u2013 Summary of Product Characteristics. (2018). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gazyvaro"},{"key":"e_1_3_3_14_2","unstructured":"Roche Pharma AG. Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V \u2013 Obinutuzumab (Gazyvaro) \u2013 Modul 3 A. (2017). https:\/\/www.g-ba.de\/downloads\/92-975-2137\/2017-09-21_Modul1_Obinutuzumab.pdf"},{"issue":"2","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14737167.2019.1522501","article-title":"Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study","volume":"19","author":"Himmler S","year":"2019","unstructured":"Himmler S, M\u00fcller M, Ostwald D, Seddik A, Basic E, Hradetzky E. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study. Expert Rev. Pharmacoecon. Outcomes Res. 19(2), 223\u2013230 (2019).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"3","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","article-title":"The impact of follicular lymphoma on health-related quality of life","volume":"19","author":"Pettengell R","year":"2008","unstructured":"Pettengell R, Donatti C, Hoskin P The impact of follicular lymphoma on health-related quality of life. Ann. Oncol. 19(3), 570\u2013576 (2008).","journal-title":"Ann. Oncol."},{"key":"e_1_3_3_17_2","article-title":"Cooking, caring and volunteering: unpaid work around the world","author":"Miranda V","year":"2011","unstructured":"Miranda V. Cooking, caring and volunteering: unpaid work around the world. OECD Soc. Employ. Migr. Work. Pap. No. 116 doi:10.1787\/5kghrjm8s142-en (2011) (Online).","journal-title":"OECD Soc. Employ. Migr. Work. Pap. No. 116"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.socscimed.2015.09.008","article-title":"Unpaid work in health economic evaluations","volume":"144","author":"Krol M","year":"2015","unstructured":"Krol M, Brouwer W. Unpaid work in health economic evaluations. Soc. Sci. Med. 144, 127\u2013137 (2015).","journal-title":"Soc. Sci. Med."},{"key":"e_1_3_3_19_2","volume-title":"Statistisches Jahrbuch 2016 \u2013 Kapitel 13 \u2013 Arbeitsmarkt.","author":"Destatis","year":"2016","unstructured":"Destatis. Statistisches Jahrbuch 2016 \u2013 Kapitel 13 \u2013 Arbeitsmarkt. Statistisches Bundesamt, Wiesbaden, Germany (2016)."},{"key":"e_1_3_3_20_2","volume-title":"Die Generation 65+ in Deutschland.","author":"Destatis","year":"2015","unstructured":"Destatis. Die Generation 65+ in Deutschland. Statistisches Bundesamt, Wiesbaden, Germany (2015)."},{"issue":"11","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/S0959-8049(03)00364-2","article-title":"Cancer, fatigue and the return of patients to work \u2013 a prospective cohort study","volume":"39","author":"Spelten ER","year":"2003","unstructured":"Spelten ER, Verbeek JHAM, Uitterhoeve ALJ Cancer, fatigue and the return of patients to work \u2013 a prospective cohort study. Eur. J. Cancer 39(11), 1562\u20131567 (2003).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s11764-013-0300-z","article-title":"Type of hematological malignancy is crucial for the return to work prognosis: a register-based cohort study","volume":"7","author":"Horsboel TA","year":"2013","unstructured":"Horsboel TA, Nielsen CV, Nielsen B, Jensen C, Andersen NT, de Thurah A. Type of hematological malignancy is crucial for the return to work prognosis: a register-based cohort study. J. Cancer Surviv. 7(4), 614\u2013623 (2013).","journal-title":"J. Cancer Surviv."},{"issue":"6","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/cncr.20912","article-title":"Employment pathways in a large cohort of adult cancer survivors","volume":"103","author":"Short PF","year":"2005","unstructured":"Short PF, Vasey JJ, Tunceli K. Employment pathways in a large cohort of adult cancer survivors. Cancer 103(6), 1292\u20131301 (2005).","journal-title":"Cancer"},{"issue":"17","key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/jnci\/djh255","article-title":"Burden of illness in cancer survivors: findings from a population-based national sample","volume":"96","author":"Yabroff KR","year":"2004","unstructured":"Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J. Natl Cancer Inst. 96(17), 1322\u20131330 (2004).","journal-title":"J. Natl Cancer Inst."},{"issue":"5","key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/pon.1404","article-title":"The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity \u2013 a preliminary analysis","volume":"18","author":"Cheung MC","year":"2009","unstructured":"Cheung MC, Imrie KR, Friedlich J, Buckstein R, Lathia N, Mittmann N. The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity \u2013 a preliminary analysis. Psychooncology 18(5), 554\u2013559 (2009).","journal-title":"Psychooncology"},{"issue":"3","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/10428194.2011.613132","article-title":"The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma","volume":"53","author":"Andresen S","year":"2012","unstructured":"Andresen S, Brandt J, Dietrich S, Memmer M-L, Ho AD, Witzens-Harig M. The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma. Leuk. Lymphoma 53(3), 386\u2013393 (2012).","journal-title":"Leuk. Lymphoma"},{"key":"e_1_3_3_27_2","volume-title":"Volkswirtschaftliche Gesamtrechnung: Inlandsproduktberechnung Detaillierte Jahresergebnisse 2015.","author":"Destatis","year":"2016","unstructured":"Destatis. Volkswirtschaftliche Gesamtrechnung: Inlandsproduktberechnung Detaillierte Jahresergebnisse 2015. Chapter: Fachserie 18, Reihe 1.4. Statistisches Bundesamt, Wiesbaden Germany (2016)."},{"issue":"3","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2307\/1927837","article-title":"Quantitative input and output relations in the economic systems of the United States","volume":"18","author":"Leontief WW","year":"1936","unstructured":"Leontief WW. Quantitative input and output relations in the economic systems of the United States. Rev. Econ. Stat. 18(3), 105 (1936).","journal-title":"Rev. Econ. Stat."},{"key":"e_1_3_3_29_2","volume-title":"Input\u2013Output Analysis: Foundations and Extensions","author":"Miller RE","year":"2012","unstructured":"Miller RE, Blair PD. Input\u2013Output Analysis: Foundations and Extensions (2nd Edition). Cambridge University Press, Cambridge, UK (2012). http:\/\/ebooks.cambridge.org\/ref\/id\/CBO9780511626982","edition":"2"},{"key":"e_1_3_3_30_2","volume-title":"Zeitverwendungserhebung - Aktivit\u00e4ten in Stunden und Minuten f\u00fcr ausgew\u00e4hlte Personengruppen - 2012\/2013.","author":"Destatis","year":"2015","unstructured":"Destatis. Zeitverwendungserhebung - Aktivit\u00e4ten in Stunden und Minuten f\u00fcr ausgew\u00e4hlte Personengruppen - 2012\/2013. Statistisches Bundesamt, Wiesbaden, Germany (2015)."},{"key":"e_1_3_3_31_2","volume-title":"Economics of Household Production.","author":"Reid MG","year":"1934","unstructured":"Reid MG. Economics of Household Production. J. Wiley & Sons, NY, USA (1934). http:\/\/archive.org\/details\/economicsofhouse00reid"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","DOI":"10.3726\/978-3-653-05475-0","volume-title":"Einfluss nicht-marktlicher T\u00e4tigkeiten auf den materiellen Wohlstand und die Einkommensverteilung in Deutschland.","author":"Hofmann S","year":"2015","unstructured":"Hofmann S. Einfluss nicht-marktlicher T\u00e4tigkeiten auf den materiellen Wohlstand und die Einkommensverteilung in Deutschland. Peter Lang International Academic Publishers, Bern, Switzerland (2015). https:\/\/www.econstor.eu\/handle\/10419\/178485"},{"issue":"4","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.socscimed.2005.06.046","article-title":"Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods","volume":"62","author":"van den Berg B","year":"2006","unstructured":"van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GAM, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc. Sci. Med. 62(4), 835\u2013845 (2006).","journal-title":"Soc. Sci. Med."},{"issue":"22","key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.V128.22.3605.3605","article-title":"What is the cost\u2013effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US?","volume":"128","author":"Guzauskas GF","year":"2016","unstructured":"Guzauskas GF, Masaquel A, Reyes C, Wilhelm K, Krivasi T, Veenstra DL. What is the cost\u2013effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US? Blood 128(22), 3605\u20133605 (2016).","journal-title":"Blood"},{"issue":"4","key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40258-018-0401-y","article-title":"Cost\u2013effectiveness of obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance versus bendamustine alone in treatment of patients with rituximab-refractory follicular lymphoma in Norway","volume":"16","author":"Haukaas FS","year":"2018","unstructured":"Haukaas FS, Ohna A, Krivasi T. Cost\u2013effectiveness of obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance versus bendamustine alone in treatment of patients with rituximab-refractory follicular lymphoma in Norway. Appl. Health Econ. Health Policy 16(4), 569\u2013577 (2018).","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"8","key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/11314820-000000000-00000","article-title":"Economic burden of follicular non-hodgkin\u2019s lymphoma","volume":"27","author":"Foster T","year":"2009","unstructured":"Foster T, Miller JD, Boye ME, Russell MW. Economic burden of follicular non-hodgkin\u2019s lymphoma. Pharmacoeconomics 27(8), 657\u2013679 (2009).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.socscimed.2015.09.008","article-title":"Unpaid work in health economic evaluations","volume":"144","author":"Krol M","year":"2015","unstructured":"Krol M, Brouwer W. Unpaid work in health economic evaluations. Soc. Sci. Med. 144, 127\u2013137 (2015).","journal-title":"Soc. Sci. Med."},{"issue":"6","key":"e_1_3_3_38_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/nur.20461","article-title":"Work productivity and health of informal caregivers of persons with advanced cancer","volume":"34","author":"Mazanec SR","year":"2011","unstructured":"Mazanec SR, Daly BJ, Douglas SL, Lipson AR. Work productivity and health of informal caregivers of persons with advanced cancer. Res. Nurs. Health 34(6), 483\u2013495 (2011).","journal-title":"Res. Nurs. Health"},{"key":"e_1_3_3_39_2","unstructured":"Paris V Belloni A. Value in pharmaceutical pricing (2013). https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/value-in-pharmaceutical-pricing_5k43jc9v6knx-en"},{"issue":"4","key":"e_1_3_3_40_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10198-015-0685-x","article-title":"A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs","volume":"17","author":"Krol M","year":"2016","unstructured":"Krol M, Papenburg J, Tan SS, Brouwer W, Hakkaart L. A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. Eur. J. Health Econ. 17(4), 391\u2013402 (2016).","journal-title":"Eur. J. Health Econ."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:32:59Z","timestamp":1679229179000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":38,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.2217\/cer-2020-0131"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0131","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}